Loading…
Enanta Pharmaceuticals, Inc. is projected to rise to $15.80 by 2027, a +20% move from its current price of $13.19. ENTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.91 | $13.19 | $13.47 | -0.03% |
| May 30 | $12.79 | $13.18 | $13.59 | -0.05% |
| May 31 | $12.70 | $13.18 | $13.68 | -0.08% |
| Jun 1 | $12.62 | $13.18 | $13.75 | -0.11% |
| Jun 2 | $12.56 | $13.17 | $13.82 | -0.14% |
| Jun 3 | $12.49 | $13.17 | $13.88 | -0.16% |
| Jun 4 | $12.44 | $13.17 | $13.93 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.44 | $13.17 | $13.93 | -0.19% |
| Week 2 | $12.13 | $13.14 | $14.24 | -0.38% |
| Week 3 | $11.89 | $13.12 | $14.47 | -0.57% |
| Week 4 | $11.69 | $13.09 | $14.66 | -0.75% |
| Week 5 | $11.51 | $13.07 | $14.83 | -0.94% |
| Week 6 | $11.35 | $13.04 | $14.99 | -1.13% |
| Week 7 | $11.20 | $13.02 | $15.12 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. trades in the Healthcare sector. The stock is currently priced at $13.95 and has a market cap of $405.64M, with a rank of 3214.
The current price and market position place Enanta within a mid-cap, healthcare-focused landscape. The price outlook shown in the forecast begins with a neutral stance in 2026 and shifts to a bullish trajectory in subsequent years, marked by rising average prices and ROIs through 2050.
A major floor 11.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 17.2% above — a clean break opens room to run.
A major ceiling 22.9% above — clearing it would confirm fresh momentum.
Key ENTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.62 | Sell | $13.55 | Sell |
| MA 10 | $13.66 | Sell | $13.74 | Sell |
| MA 20 | $14.17 | Sell | $13.89 | Sell |
| MA 50 | $13.64 | Sell | $13.82 | Sell |
| MA 100 | $13.62 | Sell | $13.47 | Sell |
| MA 200 | $12.40 | Buy | $12.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.66 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -114.67 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -14.02 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.42 | Sell |
| Ultimate (7,14,28) | 38.28 | Neutral |
| Momentum (10) | -1.34 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 13.61 | Sell |
| ADX (14) | 13.83 | Neutral |
| ATR (14) | 0.29 | Info |
The 30-day technical picture is Neutral with RSI at 50. SMA(50) is $13.61 and SMA(200) is $12.33, framing a gently constructive near-term path. The security shows a near-term support at $13.24 and resistance at $15.46, with a 30-day price range of $12.12 to $16.05.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.08 | $13.19 | $16.74 | 0% | Neutral | |
| $12.79 | $15.80 | $20.51 | +20% | Neutral | |
| $15.09 | $19.03 | $25.42 | +44% | Bullish | |
| $16.13 | $20.70 | $28.30 | +57% | Bullish | |
| $17.18 | $22.38 | $31.21 | +70% | Bullish | |
| $17.69 | $23.37 | $33.15 | +77% | Bullish | |
| $18.49 | $24.75 | $35.65 | +88% | Bullish | |
| $19.53 | $26.46 | $38.67 | +101% | Bullish | |
| $21.14 | $28.97 | $42.89 | +120% | Bullish | |
| $25.62 | $35.49 | $53.19 | +169% | Bullish | |
| $30.05 | $43.73 | $68.98 | +232% | Bullish | |
| $59.27 | $93.66 | $159.42 | +610% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.08 | $13.19 | $15.47 | +0.00% |
| June 2026 | $11.19 | $13.09 | $15.61 | -0.80% |
| July 2026 | $10.94 | $12.87 | $15.52 | -1.65% |
| August 2026 | $11.07 | $13.09 | $15.92 | +1.72% |
| September 2026 | $11.07 | $13.14 | $16.09 | +0.41% |
| October 2026 | $10.75 | $12.82 | $15.79 | -2.44% |
| November 2026 | $10.80 | $12.92 | $16.00 | +0.74% |
| December 2026 | $11.21 | $13.45 | $16.74 | +4.13% |
Click any year to see its month-by-month ENTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENTA to range from $12.08 to $16.74 through 2026. The $13.19 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ENTA price prediction for 2027 points to an average of $15.80 (low $12.79, high $20.51) — a potential gain of +20% on today's $13.19. Price action looks broadly range-bound.
In 2028, ENTA is projected to trade between $15.09 and $25.42, averaging $19.03 — a potential gain of +44% from today's $13.19. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Enanta Pharmaceuticals, Inc.'s 2029 outlook centres on $20.70, within a $16.13 to $28.30 range. That is up +9% on the projected 2028 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2030, ENTA could reach as high as $31.21, with a base case around $22.38 and support toward $17.18 — roughly +70% from $13.19. Buyers look set to stay in control over this stretch.
Expect ENTA to range from $17.69 to $33.15 through 2031. The $23.37 average target implies a +77% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The ENTA price prediction for 2032 points to an average of $24.75 (low $18.49, high $35.65) — a potential gain of +88% on today's $13.19. Buyers look set to stay in control over this stretch.
In 2033, ENTA is projected to trade between $19.53 and $38.67, averaging $26.46 — a potential gain of +101% from today's $13.19. That is up +7% on the projected 2032 average. Momentum favours further upside here.
Enanta Pharmaceuticals, Inc.'s 2034 outlook centres on $28.97, within a $21.14 to $42.89 range. That is up +9% on the projected 2033 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ENTA could reach as high as $53.19, with a base case around $35.49 and support toward $25.62 — roughly +169% from $13.19. Momentum favours further upside here.
Expect ENTA to range from $30.05 to $68.98 through 2040. The $43.73 average target implies a +232% move from current prices. That is up +23% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ENTA price prediction for 2050 points to an average of $93.66 (low $59.27, high $159.42) — a potential gain of +610% on today's $13.19. Momentum favours further upside here.
Investing $1,000 in ENTA today (≈ 75.815011 ENTA) could be worth
$7,101.03
+$6,101.03 (+610%) by 2050 · US Dollar
Based on the average projected ENTA price of $93.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENTAwould be worth at today's price.
$1,000 invested in ENTA on May 27, 2025 (≈ 171.821301 ENTA) would be worth
$2,266.32
+$1,266.32 (+126.6%) today · 2.27× · US Dollar
Based on a ENTA entry price of $5.82 vs. today's $13.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.61 | $969.14 | -3.1% |
| 1 month ago | $13.28 | $993.22 | -0.7% |
| 3 months ago | $14.41 | $915.34 | -8.5% |
| 6 months ago | $14.12 | $934.14 | -6.6% |
| 1 year ago | $5.82 | $2,266.32 | +126.6% |
| All time (5.0y) ago | $47.18 | $279.57 | -72.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENTA forecast.
Our base-case forecast reaches $26.00 around 2033.
Implied market cap at $26.00: $756.04M
The multi-year forecast begins with 2026, which shows a min of $12.08, an avg of $13.95, and a max of $17.98, with a neutral sentiment and ROI of 0%. From 2027 onward the outlook is bullish, with 2027 avg $17.17 and ROI 23.1%, 2028 avg $21.01 and ROI 50.6%, 2029 avg $22.92 and ROI 64.3%, and 2030 avg $24.88 with ROI 78.3%. Key later milestones include 2031 avg $26.41, 2032 avg $28.05, 2033 avg $30.18, 2034 avg $33.80, 2035 avg $41.25, 2040 avg $51.96 with ROI 272.5%, and 2050 avg $112.67 with ROI 707.7%.
The 2030, 2040, and 2050 figures illustrate a long-run bullish trajectory, with max values reaching $34.65 in 2030, $81.82 in 2040, and $191.33 in 2050. These are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $24.88, min $19.11, max $34.65, ROI 78.3%, sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward with rising averages and ROIs (e.g., avg $24.88 in 2030 and avg $112.67 in 2050 with ROI of 78.3% and 707.7% respectively), but these are estimates, not guarantees.
Yes. The 2050 forecast shows avg $112.67 and max $191.33, indicating potential to exceed $100; earlier years peak below $100.
Current price is $13.95 and market cap is $405.64M.
Min $12.08, avg $13.95, max $17.98, ROI 0, sentiment NEUTRAL.
Enanta Pharmaceuticals, Inc. Community Discussion
0Share your Enanta Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.